全文获取类型
收费全文 | 8998篇 |
免费 | 717篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 92篇 |
儿科学 | 293篇 |
妇产科学 | 170篇 |
基础医学 | 1360篇 |
口腔科学 | 144篇 |
临床医学 | 1129篇 |
内科学 | 1714篇 |
皮肤病学 | 175篇 |
神经病学 | 877篇 |
特种医学 | 181篇 |
外科学 | 898篇 |
综合类 | 55篇 |
一般理论 | 8篇 |
预防医学 | 1425篇 |
眼科学 | 111篇 |
药学 | 519篇 |
中国医学 | 4篇 |
肿瘤学 | 574篇 |
出版年
2024年 | 14篇 |
2023年 | 119篇 |
2022年 | 171篇 |
2021年 | 313篇 |
2020年 | 218篇 |
2019年 | 327篇 |
2018年 | 302篇 |
2017年 | 285篇 |
2016年 | 296篇 |
2015年 | 324篇 |
2014年 | 403篇 |
2013年 | 536篇 |
2012年 | 832篇 |
2011年 | 816篇 |
2010年 | 438篇 |
2009年 | 405篇 |
2008年 | 658篇 |
2007年 | 631篇 |
2006年 | 576篇 |
2005年 | 518篇 |
2004年 | 419篇 |
2003年 | 344篇 |
2002年 | 296篇 |
2001年 | 38篇 |
2000年 | 36篇 |
1999年 | 45篇 |
1998年 | 31篇 |
1997年 | 34篇 |
1996年 | 32篇 |
1995年 | 33篇 |
1994年 | 30篇 |
1993年 | 24篇 |
1992年 | 14篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 12篇 |
1988年 | 15篇 |
1987年 | 11篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 13篇 |
1982年 | 10篇 |
1981年 | 7篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1976年 | 3篇 |
1912年 | 2篇 |
排序方式: 共有9729条查询结果,搜索用时 46 毫秒
991.
992.
Mohamad A Mikati MD Yong‐hui Jiang MD PhD Michael Carboni MD Vandana Shashi MD Slave Petrovski PhD Rebecca Spillmann PhD Carol J. Milligan PhD Melody Li PhD Annette Grefe MD Allyn McConkie PhD Samuel Berkovic MD Ingrid Scheffer MD Saul Mullen MD Melanie Bonner PhD Steven Petrou PhD David Goldstein PhD 《Annals of neurology》2015,78(6):995-999
We report 2 patients with drug‐resistant epilepsy caused by KCNT1 mutations who were treated with quinidine. Both mutations manifested gain of function in vitro, showing increased current that was reduced by quinidine. One, who had epilepsy of infancy with migrating focal seizures, had 80% reduction in seizure frequency as recorded in seizure diaries, and partially validated by objective seizure evaluation on EEG. The other, who had a novel phenotype, with severe nocturnal focal and secondary generalized seizures starting in early childhood with developmental regression, did not improve. Although quinidine represents an encouraging opportunity for therapeutic benefits, our experience suggests caution in its application and supports the need to identify more targeted drugs for KCNT1 epilepsies. Ann Neurol 2015;78:995–999 相似文献
993.
Tim L. Th. A. Jansen Nicola Dalbeth Jaap Fransen H. Ralph Schumacher Dianne Berendsen Melanie Brown Hyon Choi N. Lawrence Edwards Hein J. E. M. Janssens Frédéric Lioté Raymond P. Naden George Nuki Alexis Ogdie Fernando Perez‐Ruiz Kenneth Saag Jasvinder A. Singh John S. Sundy Anne‐Kathrin Tausche Janitzia Vaquez‐Mellado Steven A. Yarows William J. Taylor 《Arthritis \u0026amp; Rheumatology》2015,67(10):2557-2568
994.
995.
Using the Effects of Youngsters’ Eyesight on Quality of Life Questionnaire to Measure Visual Outcomes in Children With Uveitis
下载免费PDF全文
![点击此处可从《Arthritis care & research》网站下载免费的PDF全文](/ch/ext_images/free.gif)
996.
997.
998.
Does Systolic Blood Pressure Response to Lifestyle Intervention Indicate Metabolic Risk and Health‐Related Quality‐of‐Life Improvement Over 1 Year?
下载免费PDF全文
![点击此处可从《Journal of clinical hypertension (Greenwich, Conn.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Melanie I. Stuckey PhD Dawn P. Gill PhD Robert J. Petrella MD PhD 《Journal of clinical hypertension (Greenwich, Conn.)》2015,17(5):375-380
The purpose of this study was to determine whether responders (minimum 4‐mm Hg reduction of systolic blood pressure [BP]) at 24 weeks) to a 52‐week lifestyle intervention had greater changes in metabolic risk factors and health‐related quality of life than nonresponders. Participants (N=126; age, 57.4 [9.1] years) had waist circumference (WC), resting BP, glycated hemoglobin, lipids, and fitness assessed at baseline and at 12, 24, and 52 months. The 36‐item short‐form survey was administered to assess HRQOL. At baseline, responders had higher mental health scores (P=.04) and systolic and diastolic BPs (P<.001) than nonresponders. Across 52 weeks, responders also had greater improvements in diastolic BP (P<.001), WC (P=.01), and maximal oxygen uptake (P=.04) compared with nonresponders. Participants with clinically important changes in systolic BP at 24 weeks had greater metabolic improvements across 52 weeks, compared with those without clinically important systolic BP changes. 相似文献
999.
Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology
下载免费PDF全文
![点击此处可从《Genes, chromosomes & cancer》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Nicole Pfarr Silvia Darb‐Esfahani Jonas Leichsenring Eliane Taube Melanie Boxberg Ioana Braicu Moritz Jesinghaus Roland Penzel Volker Endris Aurelia Noske Wilko Weichert Peter Schirmacher Carsten Denkert Albrecht Stenzinger 《Genes, chromosomes & cancer》2017,56(10):758-766
Brenner tumors (BT) are rare ovarian tumors encompassing benign, borderline, and malignant variants. While the histopathology of BTs and their clinical course is well described, little is known about the underlying genetic defects. We employed targeted next generation sequencing to analyze the mutational landscape in a cohort of 23 BT cases (17 benign, 2 borderline, and 4 malignant) and 3 ovarian carcinomas with transitional cell histology (TCC). Copy number variations (CNV) were validated by fluorescence in‐situ hybridization (FISH) and quantitative PCR‐based copy number assays. Additionally, we analyzed the TERT promotor region by conventional Sanger sequencing. We identified 25 different point mutations in 23 of the analyzed genes in BTs and 10 mutations in 8 genes in TCCs. About 57% percent of mutations occurred in genes involved in cell cycle control, DNA repair, and epigenetic regulation processes. All TCC cases harbored TP53 mutations whereas all BTs were negative and none of the mutations observed in BTs were present in TCCs. CNV analysis revealed recurrent MDM2 amplifications in 3 out of 4 of the malignant BT cases with one case harboring a concomitant amplification of CCND1. No mutations were observed in the TERT promoter region in BTs and TCCs, which is mutated in about 50%‐75% of urothelial carcinoma and in 16% of ovarian clear‐cell carcinomas. In conclusion, our study highlights distinct genetic features of BTs, and detection of the triplet phenotype MDM2 amplification/TP53 wt/TERT wt may aid diagnosis of malignant BT in difficult cases. Moreover, selected genetic lesions may be clinically exploitable in a metastatic setting. 相似文献
1000.
Melanie Rammer Gerald Webersinke Sophie Haitchi-Petnehazy Eva Maier Hubert Hackl Pornpimol Charoentong Theodora Malli Maria Steinmair Andreas L. Petzer Holger Rumpold 《Clinical & experimental metastasis》2017,34(6-7):431-440
Worldwide, colon cancer is among the most common cancer entities. Understanding the molecular background is the key to enable accurate stage determination, which is crucial to assess optimal therapy options. The search for preoperative biomarkers is ongoing. In recent years, several studies have proposed a diagnostic and prognostic role for miRNAs in cancer. Aim of this study was to evaluate miRNA expression patterns correlating with tumor stage, especially lymph node metastasis, in primary colon carcinoma tissue. Screening was accomplished using GeneChip® miRNA v3.0 arrays (Thermo Fisher Scientific, Waltham, MA, USA) and validated via TaqMan® qPCR assays (Thermo Fisher Scientific, Waltham, MA, USA) to investigate miRNA expressions in 168 FFPE and 83 fresh frozen colon carcinoma samples. Regarding lymph node status, analyses displayed no significantly differential miRNA expression. Interestingly, divergent expression of miR-18a-5p, miR-20a-5p, miR-21-5p, miR-152-3p and miR-1973 was detected in stage pT1. Although miRNAs might not represent reliable biomarkers regarding lymph node metastasis status, they could support risk assessment in stage T1 tumors. 相似文献